Abs#0501 @RheumNow #ACR23 Uveitis in SpA, from Greece AxSpA: 11.7% Uveitis. RF: HLA-B27 (OR 4.15), periperhal arthritis (OR 3.05) PsA: 2.7% Uveitis. Ass w/ SpA FHx, Axial dis at dx, disease duration Permanent vision loss in 16% AxSpA, 30% PsA pts, all with recurrent uveitis

EISER study: Undiagnosed IBD in SpA Abs#0495 #ACR23 @RheumNow 559 pts, 47% PsA/53% SpA (80% r-AxSpA) Higher mean fecal calprotectin in r-AxSpA (395 vs 305 nrAxSpA/PsA) 14.6% IBD symptoms, 23 patients (4.4% were dx w IBD) Fecal calprotectin & history can uncover IBD #ACRBest

#ACR23 Please find my preview article on selected #SLE abstracts to be presented at year’s conference - towards Glucocorticoid-Free zone in lupus @RheumNow https://t.co/1kM7LWc64V https://t.co/WK9X7UpsNi

High hs-CRP predicts PsO -> PsA? Abs#0484 #ACR23 @RheumNow 589 PsO pts wo PsA, followed mean 7.5 years 57 pts developed PsA (1.2 events/yr) Higher levels of b/l hs-CRP seen w: arthrlalgia, obesity, females Higher hs-CRP ass. w/ PsA - p=0.002, but HR only 1.03 (CI 1.01-1.05)

Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/vucBYeM1P5 https://t.co/YqdqZWFhfd

• Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analy…

In young patients who have a spinal MRI, lesions are reported in most patients, and similar in males:females. SIJ MRI findings are reported in one out of three patients, being more frequently in males @DiegoBenavent Abst #160 #ACR23 @RheumNow https://t.co/aF9WnP7jpY https://t.co/E9UuZ0sWZm

#Benefits of #hudroxychloroquine - reduced lipids, clots, CV events, infection AND now improved #fatty #liver #NAFLD….@RheumNow #ACR23 @ACRheum https://t.co/Y43JETY6F3

Sarilumab for relapsing of PMR. Any thing to to taper off prednisone quickly. #ACR23 , year in review. Lost of good studies and smart discussions @RheumNow at Make rheum for PMR month. https://t.co/VyRP8ls3OC

Thank you @synovialjoints @RheumNow for highlighting our work #ACR23 #ACRambassador @ACRheum @ArLARheumatolog #ARCH_ArLAR https://t.co/rphaODphD1

If successful you may need how to pronounce these emerging therapeutics in #inflammatory #arthritis @RheumNow #ACR23 @ACRheum https://t.co/aOogwQCsCM

One for you, one for me! So many pasalubong char @RHEUMarampa @RheumNow #acr23 #ACRambassador https://t.co/v0mZ9vbadx

• https://twitter.com/rheumarhyme/status/1723791933263245556/photo/1

Cellular based biology explanation of sex bias in ARDs 👀 Data from AMP w/ sc-RNA seq from synovial tissue shows: Enriched inflammatory pathways in females synovial macrophages clusters vs. males Basis for gender specific treatment strategies? @RheumNow ABST0724 #ACR23 https://t.co/1p8PDIRNoI

Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels? Radiographic progression equally low in both drugs NO difference in syndesmophytes or CRP @RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE

In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH ✳️TRAF5 deficiency activates BMP/TGFB signaling w/⬆️PAEC apoptosis ✳️TRAF5 overexpression attenuated PAH sxs in mice TRAF5 as potential BM for dx/novel tx target in SLE-PAH? #ACR23 ABST0723 @RheumNow https://t.co/WT9vQo8y8s

Important plenary re:reduced vs standard GC for AAV... IRL PEXIVAS & recent guidelines supported low dose taper Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts Need full data but yikes... @RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok